The FDA has extended the review period for the NDA for aficamten for the treatment of patients with obstructive hypertrophic cardiomyopathy.

The table below is a review of notable updates that occurred in April 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage. Drug ...

A study was conducted to examine gender and sociodemographic disparities in ICD access for patients with high-risk heart failure.

In patients with nickel hypersensitivity, there is increased risk for device syndrome within the first 90 days following patent foramen ovale closure.

A scientific statement has been published by the American Heart Association regarding the effect of sleep health on cardiometabolic health.

Average and brisk walking pace are associated with a decreased risk for all cardiac arrhythmias, atrial fibrillation, and other arrhythmias.

Exposure to antihypertensives, NSAIDs, and statins showed a strong correlation with older Parkinson disease age at onset, while smoking and family history, however, correlated with younger age at ...

Both dual use of traditional and e-cigarettes and exclusive cigarette use are associated with higher toxicant exposure than exclusive e-cigarette use.

The Prescription Drug User Fee Act (PDUFA) date refers to the deadline set by the US Food and Drug Administration (FDA) for reviewing a New Drug Application (NDA) or Biologics Lic ...

The Food and Drug Administration (FDA) has cleared the Jewel® Patch Wearable Cardioverter Defibrillator (Patch-WCD).

Tirzapetide dose escalation schedules were slower in the real-world than clinical settings among individuals with obesity without T2D.

Compared with White patients, Hispanic and Asian patients are less likely to be referred for outpatient heart failure management programs.